Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin + Irinotecan vs Carboplatin + Etoposide in SCLC
NCT00168896Phase 3Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of irinotecan in small cell lung cancer (SCLC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Objective Remission Rate and Progression-Free Survival. Status: unknown.
02
Drugs
irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00168896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168896.